Asahi shares mark weekly slide after cyberattack halts production
Eric W. Roberts, Chief Business Officer at CalciMedica, Inc. (NASDAQ:CALC), a $47 million market cap biotech company, reported purchasing 2,343 shares of common stock on September 9, 2025. The timing appears strategic, as InvestingPro data shows CALC has delivered a 10% return in the past week. The shares were bought at a weighted average price of $3.1488, for a total transaction value of $7377. The prices for the shares ranged from $2.75 to $3.21
Following the transaction, Roberts directly holds 179,706 shares. Indirectly, Roberts holds 73,250 shares By FMTC Custodian - Roth IRA FBO Eric W. Roberts, 49,894 shares By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA, 10,661 shares By IRA Financial Trust Company CFBO Eric W. Roberts, 356,989 shares By Valence Investments SPV IV, LLC, 66,228 shares By Valence Investments SPV V, LLC and 316,109 shares By Valence Investments SPV VI, LLC.
In other recent news, CalciMedica Inc. has shared details about its Phase 2 KOURAGE trial for Auxora, a treatment for acute kidney injury (AKI) with respiratory failure. The company published a manuscript in the American Journal of Nephrology, outlining the trial’s design and rationale. The publication includes preclinical data indicating that Auxora significantly increased the glomerular filtration rate in rat models of AKI. Additionally, a post-hoc analysis from the CARDEA trial revealed a 62.7% relative reduction in mortality among COVID-19 patients with AKI who received Auxora compared to those given a placebo. These developments are part of CalciMedica’s ongoing efforts to advance its treatment for AKI. The details provided in the manuscript aim to support the scientific community’s understanding of Auxora’s potential benefits. This information could be of interest to investors monitoring advancements in medical treatments for kidney-related conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.